The indication is based on a phase 3 trial – Empower-Lung 1 – that showed Libtayo given as a monotherapy cut the risk of death by 43% compared to chemotherapy in advanced, PD-L1-high patients ...

Libtayo was a late entrant into the PD-1/PD ... The two partners are hoping to grow the drug with new indications such as basal cell carcinoma – another form of skin cancer – and non-small ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

However, they are U.S. Food and Drug Administration (FDA)-approved for different indications (uses). Ibuprofen and DayQuil are drugs in different classes with different mechanisms of action. Ibuprofen ...